London, UK - The UK's financial sector has been dealt another blow as investment firm H.C. Wainwright cut its target share price for biotech company Structure Therapeutics to $70 from $100.
The move is the latest in a series of downward revisions in the stock market, with many analysts warning of an impending downturn due to global economic uncertainty and rising inflation.
Structure Therapeutics' shares have been under pressure recently, sliding by over 20% in the past month alone. The company's struggles are reflective of broader issues facing biotech firms, including funding challenges and regulatory hurdles that make it increasingly difficult for them to secure vital investment.
The UK's biotech sector is a significant contributor to the country's economy, with many experts warning that further setbacks could have far-reaching implications for employment, research, and innovation. The industry has faced increased scrutiny in recent months, with several high-profile companies facing funding challenges and regulatory hurdles.